CLAYTON, N.C., June 21 /PRNewswire-FirstCall/ -- Tomorrow, Novo Nordisk, a world leader in diabetes care, will open its $100 million, 200,000-square-foot expanded facility in Clayton, North Carolina to meet the country's increasing demand for FlexPen(R), the world's number one selling popular prefilled insulin pen. The event marks the second expansion in three years of the company's only insulin manufacturing facility in the United States, doubling the company's domestic insulin filling capabilities and initiating the first domestic production of FlexPen(R). As a result, more than 50 jobs have been created. To date, Novo Nordisk has expanded its workforce in Clayton to 400. "Novo Nordisk is proud to both open the door to exciting job opportunities in Johnston County, with its wealth of intellectual talent and skilled labor, and to expand access to safe and effective insulin products made in the United States," said Lars Nobert, vice president of the facility. "With this new commitment of resources in the United States, Novo Nordisk is fulfilling its pledge to change diabetes by helping to improve the lives of the millions of Americans living with the disease." The company has a Triple Bottom Line commitment to social and environmental responsibility. To date, more than 3,000 adults have completed courses at the Johnston County Workforce Development Center, an award-winning learning center made possible through donations, including a land donation for the center from Novo Nordisk. "By cultivating and maintaining an educated work force and creating exciting jobs in pharmaceutical manufacturing, Novo Nordisk is providing access to some of the best paying and most rewarding opportunities in the area," said Mike DeSherbinin, Director of the Johnston County Economic Development Office. The company has a history of social responsibility in the community. Last year the company raised $20,000 for the Johnston County United Way and is a regular contributor to the Juvenile Diabetes Research Foundation. To recognize its Danish heritage and enrich local high school principals and teachers, the company also sponsors a Danish-American exchange for educators. "Novo Nordisk is a valued partner in the community offering local area residents one of the best possible work environments in the area, exciting training and career advancement programs, and generous donations," said Clayton Town Manager, Steve Biggs. "The company has demonstrated both leadership in the community and an ability to successfully manage growth and changes in Clayton." Approximately 54 million Americans have pre-diabetes, a condition that puts them at increased risk for diabetes, a chronic disease affecting nearly 21 millions Americans. Many people with diabetes take insulin to control their blood sugar (glucose). Insulin pens can be used instead of vials and syringes for giving insulin injections. FlexPen is exclusively available for use with the Novo Nordisk insulin analog product portfolio. Novo Nordisk Pharmaceutical Industries in Clayton is located on 3612 Powhatan Road. The opening ceremony will take place Friday from noon until one o'clock. About Novo Nordisk Novo Nordisk is a healthcare company with an 84-year history of innovation and achievement in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems. In addition to diabetes care, Novo Nordisk has a leading position within areas such as hemostasis management, growth hormone therapy, and hormone therapy for women. Novo Nordisk's business is driven by the Triple Bottom Line: a commitment to economic success, environmental soundness, and social responsibility to employees and customers. With headquarters in Denmark, Novo Nordisk employs more than 23,600 employees in 79 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For global information, visit novonordisk.com; for United States information, visit novonordisk-us.com.
SOURCE Novo Nordisk Inc.